São Paulo Government Claims Coronavac Achieved 78% Efficacy in Brazilian Trials

The Butantan Institute is negotiating future exports of the Coronavac. Dimas Covas states that at least six countries have already started discussions: Argentina, Peru, Bolivia, Uruguay, Honduras, and Ecuador.

RIO DE JANEIRO, BRAZIL - Studies have shown that the Butantan vaccine is 100% effective for severe and moderate cases, but pressure is growing for details to be disclosed. Emergency use should be officially requested by Friday, January 8th.

The Coronavac, a vaccine developed by the Chinese Sinovac laboratory together with the Butantan Institute, showed 78% efficacy against Covid-19 in the trial developed in Brazil and sponsored by the Government of São Paulo, according to the state health authorities.

The immunizer, at the center of a political feud between President Jair Bolsonaro and Governor João Doria, also ensured . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?